Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update [Yahoo! Finance]
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: Yahoo! Finance
FDA granted Fast Track designation to KT-621 for the treatment of moderate to severe asthma, in addition to prior Fast Track designation for moderate to severe atopic dermatitis KT-579 (IRF5) Phase 1 healthy volunteer trial ongoing, with data expected in 2H26 Gilead Sciences exercised its option to exclusively license KT-200, a first-in-class, oral CDK2 molecular glue degrader, generating a $45 million milestone, with IND planned in 2027 Well-capitalized with $1.55 billion in cash as of March 31, 2026, and runway into 2029 Company to hold video conference call and webcast today at 8:30 a.m. ET WATERTOWN, Mass., April 30, 2026 (GLOBE NEWSWIRE) Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today reported financial results for the first quarter ended March 31, 2026, and provided business highlights and updates on its pipeline. “As we continue to
Show less
Read more
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business UpdateGlobeNewswire
- Infinimmune Appoints Anthony Slavin, Ph.D., as Senior Vice President of Portfolio Strategy [Yahoo! Finance]Yahoo! Finance
- A Look At Kymera Therapeutics (KYMR) Valuation After Fast Track News And Gilead Collaboration Progress [Yahoo! Finance]Yahoo! Finance
- FDA Grants Fast Track Designation to Kymera Therapeutics, Inc. (KYMR)'s KT-621 for Eosinophilic Asthma [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026GlobeNewswire
KYMR
Earnings
- 4/30/26 - Beat
KYMR
Sec Filings
- 4/30/26 - Form 10-Q
- 4/30/26 - Form 8-K
- 4/29/26 - Form 4
- KYMR's page on the SEC website